34 results
To determine the efficacy and safety of laser therapy in diabetes patients with risk factors for developing diabetic foot complications.
Primary objective:1. To evaluate the frequency of invasive fungal infections in a prospective pediatric oncology cohort and to identify the determinants of such invasive infections.2. Clinical validation of novel innovative diagnostic methods for…
Establish the pharmacokinetic parameters of micafungin in critically ill patients and determine whether pharmacokinetic parameters and plasma concentrations of micafungin correlate with disease severity.
The primary objective of this trial is as follows:• To determine the pharmacokinetics of anidulafungin administered to obese patients with a BMI >= 40 kg/m2. The secondary objective of this trial is as follows:• To simulate pharmacokinetics…
Determine the pharmacokinetics of caspofungin, and the optimal dosage of caspofungin in relation to adequate exposure in critically ill patients.
- To investigate the safety and tolerability of posaconazole IV Solution (the test medication).- To study how the test compound posaconazole (the test medication) is absorbed, broken-down and excreted by the body. - To study the effect of the test…
to investigate whether the bioavailability of posaconazole in graft-versus-host-disease (GVHD) patients, adversely affected by the coadministration of proton pump inhibitors (PPIs), can be restored by an acidic beverage
Objective: The primary objective of this pilot study is to compare FDG-PET-CT with HR-CT alone and to HR-CT and galactomannan test together for early diagnosing IFIs in neutropenic patients.
Prevalence of Tinea Pedis (athlete's foot) in people with intellectual disability in The Netherlands
Study into the prevalence of Tinea Pedis in intellectually disabled people who receive care from one of four care providers in The Netherlands, either living in the community or in a centralised location. Study into the prevalence of the different…
The primary objective of this study is to evaluate the PK of POS administered orally at three dosage levels to immunocompromised children with expected neutropenia (selected oncology patients, aplastic anemia patients and patients which undergo a…
Primary Objectives:To assess the incidence and the time to confirmed IFI in subjects treated pre-emptively with micafungin versus placebo.
The study described in this protocol is designed to determine the pharmacokinetics of cefotaxime and its metabolite, desacetyl-cefotaxime, in children on continuous intravenous infusion of cefotaxime. Using these data we will be able to delineate…
This study aims to determine whether variations in genes encoding the most important components of the innate immune system (gene polymorphisms), play a role in the susceptibility to recurrent vulvovaginal candidiasis.
The primary objective of this trial is as follows:• To determine the pharmacokinetics of anidulafungin given once in every 2 days (q48h) or once in every 3 days (q72h) to patients undergoing an allogeneic haematopoietic stem cell transplant…
Primary Objectives:• To assess the effects of VOR 200 mg BID on the steady-state PK of ATV administered as ATV/RTV300/100 mg QD in healthy subjects• To assess the effects of ATV/RTV 300/100 mg QD on the steady-state PK of VOR 200 mg BID inhealthy…
To investigate the correlation of pharmacokinetic parameters of anidulafungin with markers for disease severity and plasma protein levels.
The expectation is that FDG-PET demonstrates or excludes infectious complications earlier than current practice, resulting in more efficient use of other diagnostic methods and therapy. Besides early detection and treatment of invasive fungal…
Primary: Dose finding for a twice daily regimen for PSZ as prophylactic treatment in children with CGD, based on the exposure to PSZ measured by PSZ trough levels.Secondary:To determine the tolerability of PSZ as prophylactic treatment in children…
Are fluconazole saliva levels representative for serum levels in children and neonates?
Primary objective:To determine the effect of obesity (BMI > 40kg/m2) on the pharmacokinetics of micafungin and develop a dosing regimen for obese patients. Secondary objective:* To describe the pharmacokinetics of the approved dose of 200mg…